Anti-Tyrosinase-Related Protein-2 Immune Response in Vitiligo Patients and Melanoma Patients Receiving Active-Specific Immunotherapy
- 1 December 1998
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 111 (6) , 1034-1039
- https://doi.org/10.1046/j.1523-1747.1998.00411.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaThe Journal of Experimental Medicine, 1997
- Current Status of Human Melanoma VaccinesBioDrugs, 1997
- Tyrosinase and related proteins in mammalian pigmentationFEBS Letters, 1996
- Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanomaInternational Journal of Cancer, 1996
- Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patientsInternational Journal of Cancer, 1995
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- Relation Between the Incidence and Level of Pigment Cell Antibodies and Disease Activity in VitiligoJournal of Investigative Dermatology, 1991
- Pigmentation-Associated Glycoprotein of Human Melanomas and Melanocytes: Definition with a Mouse Monoclonal AntibodyJournal of Investigative Dermatology, 1985
- A pigmentation‐associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serumInternational Journal of Cancer, 1983
- Antibodies to normal human melanocytes in vitiligo.The Journal of Experimental Medicine, 1983